Related Experiment Video
Updated: Jul 10, 2026

In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing
K W Garey1, D Lai, T K Dao-Tran
1University of Houston, College of Pharmacy, Texas Medical Center, 1441 Moursund Street, Houston, TX 77030, USA. kgarey@uh.edu
Abstract:
The increased incidence of methicillin-resistant Staphylococcus aureus (MRSA), the emergence of community-acquired MRSA, and the continued high incidence of methicillin-resistant Staphylococcus epidermidis have required that certain institutions choose vancomycin for surgical prophylaxis. However, the data supporting the use of vancomycin for surgical prophylaxis are controversial. The purpose of this project was to assess the effect of the change from cefuroxime to vancomycin for surgical site infection (SSI) rates in patients undergoing coronary artery bypass graft (CABG) surgery. The monthly rates of SSIs from 2001 to 2005 were analyzed before and after a change from cefuroxime to vancomycin antibiotic prophylaxis in patients undergoing CABG by using an interrupted time series analysis. Patients who underwent cardiac valve replacement surgery and who had received vancomycin during the entire study period were used as a comparator group. A total of 6,465 patients underwent CABG surgery (n = 4,239) or valve replacement surgery (n = 2,226) during the study period. On average, the monthly SSI incidence rate in patients undergoing CABG surgery decreased by 2.1 cases per 100 surgeries after the switch from cefuroxime to vancomycin (P = 0.042) when patients undergoing valve replacement were used as a comparator group. The change in SSI rates was associated with a decrease in the incidence of infections caused by coagulase-negative Staphylococcus and MRSA isolates, with little change in the incidence of SSIs due to other gram-positive organisms or gram-negative organisms. In institutions with a high incidence of methicillin-resistant Staphylococcus species, this study provides evidence for the clinical efficacy of vancomycin prophylaxis for the prevention of postoperative SSIs in patients undergoing CABG surgery.
Insights
Switching to vancomycin for surgical prophylaxis in coronary artery bypass graft (CABG) surgery reduced surgical site infections (SSIs). This change effectively lowered MRSA infections, demonstrating vancomycin
Area of Science:
- Infectious Diseases
- Surgical Outcomes
- Antimicrobial Stewardship
Background:
- Rising rates of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis necessitate alternative prophylactic antibiotics.
- Vancomycin use for surgical prophylaxis is debated, requiring further clinical evidence, especially for high-risk procedures like coronary artery bypass graft (CABG) surgery.
Purpose of the Study:
- To evaluate the impact of switching antibiotic prophylaxis from cefuroxime to vancomycin on surgical site infection (SSI) rates in CABG patients.
- To assess the efficacy of vancomycin in preventing SSIs in the context of increasing MRSA prevalence.
Main Methods:
- An interrupted time series analysis was employed to compare monthly SSI rates before and after the antibiotic prophylaxis change.
- Data from 2001-2005 encompassing 4,239 CABG patients and 2,226 cardiac valve replacement patients were analyzed.
- Cardiac valve replacement patients receiving vancomycin throughout served as a comparator group.
Main Results:
- A statistically significant decrease of 2.1 SSIs per 100 CABG surgeries was observed after the switch to vancomycin (P = 0.042).
- The reduction in SSIs was primarily attributed to a decrease in infections caused by coagulase-negative Staphylococcus and MRSA.
- No significant changes in SSIs caused by other gram-positive or gram-negative organisms were noted.
Conclusions:
- The transition to vancomycin prophylaxis for CABG surgery is clinically effective in reducing postoperative SSIs, particularly those caused by MRSA.
- This evidence supports the use of vancomycin in institutions facing high incidences of methicillin-resistant Staphylococcus species to prevent SSIs in CABG patients.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Antimicrobial Effectiveness
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Interval and Administration Route: Determination Methods
Endocarditis III: Medical Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management